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Summary
Lipopolysaccharide (LPS) potently stimulates human immunodeficiency virus type 1-long terminal
repeat (HIV1-LTR) CAT constructs transfected into monoryte/macrophage-like cell lines but
not a T cell line. This effect appears to be mediated through the induction of nuclear factor
KB (NF-KB) . Electrophoretic mobility shift assays demonstrate that LPS induces a DNA binding
activity indistinguishable from NF-KB in U937 and THP-1 cells.
LPS is also shown to dramatically increase HIV-1 production from a chronically infected
monoryte/macrophage-like cloned cell line, U1, which produces very low levels ofHIV-1 at baseline .
The stimulation of viral production from this cell line occurs only if these cells are treated with
granulocyte/macrophage colony-stimulating factor (GM-CSF) before treatment with LPS . This
stimulation of HIV-1 production is correlated with an increase in the level of HIV-1 RNA and
an activation of NF-KB . LPS is not able to induce HIV-1 production in a cloned T cell line .
The effect of LPS on HIV-1 replication occurs at picogram per milliliter concentrations and may
be clinically significant in understanding the variability of the natural history of HIV-1 infection .
Control of the replication of HIV-1 involves both virus-encoded proteins and cellular factors activated by a va-
riety of exogenous stimuli (1-3) . The role of cellular events
is evident because stimulation of the HIV-1 promoter within
the long terminal repeat (LTR)' is produced by various cel-
lular stimuli including phorbol esters, TNF-a, and heterolo-
gous viral proteins (3) . Many of these agents appear to func-
tion through the activation ofnuclear factor KB (NF-KB) which
binds to two 11 by motifs in the HIV-1 LTR and consequently
activates LTR-driven RNA transcription (3-7) . The effects
of certain cellular stimuli on HIV-1 replication have been
studied in transient transfection assays of the HIV1-LTR
linked to reporter genes and by utilizing chronically infected
cell lines and primary cells (3-14) .
HIV-1 growth in infected people is difficult to study directly
and so must be modeled by examining influences on cells
in culture . Factors that stimulate HIV-1 replication in cell
culture may also regulate HIV-1 expression in CD4 lympho-
cytes and monocytes/macrophages in vivo (1-3) . These are
1 Abbrndations used in this paper. CAT, chloramphenicol acetyl
transferase; GM-CSF, granulocyte/macrophage colony-stimulating
factor; LTR, long terminal repeat ; NF-KB, nuclear factor KB.
the two major cell types known to harbor HIV-1 (1) . In the
periphery, CD4 lymphocytes carry most of the virus (15),
but the monoryte/macrophage may be the major cell type
infected in the central nervous system and other tissues (1,
16, 17) . The monoryte/macrophage may act as a "Trojan
Horse," concealing the virus from the immune system, and
it may be among the first cells infected by HIV-1 in patients
(1, 17).
Many agents that stimulate HIV-1 replication do so in both
T cells and monoryte/macrophages (6-8) . With the excep-
tion of granulocyte/macrophage colony stimulating factor
(GM-CSF), agents that induce HIV-1 replication only in
monoryte/macrophages are not well described (9, 12, 14).
Stimuli that selectively affect HIV-1 replication in mono-
cyte/macrophages might, therefore, hold significant clinical
importance.
The monoryte/macrophage can be studied either directly
after culturing or through cell line models. Primary mono-
cyte/macrophages have thus far been refractory to transfec-
tion with significant efficiency, and therefore, are not suit-
able for the study ofgene expression and regulation . We have
thus chosen to study the U937 and THP-1 monoryte/mac-
rophage-like cell lines as model systems.
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In this paper, we demonstrate that LPS or endotoxin, a
constituent ofthe cell wall of gram-negativebacteria, stimu-
lates gene expression directed from theHIV1-LTR in mono-
cyte/macrophage-like cell lines but not in T cell lines. LPS
has this effect at physiologically significant concentrations and
appears to do so through the activation of NF-KB, which
in turn binds to two KB enhancer elements in the U3 region
of the HIV1-LTR (4).
Contrary to a previous report (7), we find no correlation
between the state of differentiation of the available mono-
cyte/macrophage-like cell lines and the level of constitutive
expression o£ activated NF-KB. However, we do find that ac-
tivation ofNF-KBby LPSand consequent stimulation of HIV-1
from a cloned monocyte/macrophage-like cell line (9) occur
only after treatment with GM-CSF . This suggests that the
developmental maturity of HIV-1-infected monocyte popu-
lations may determine whether they respond to LPS with
an increase in HIV-1 production .
Materials and Methods
Cells.
	
A monoblastoid cell line, U937, was maintained in RPMI
1640 media supplemented with 10% FCS, penicillin (250 U/ml), and
streptomycin (250 14g/ml) (18) . The cell line THP-I, derived from
monocytic leukemic cells, was maintained as above (19). Ahuman
Tcell lineJurkat was also maintained as previously described (20) .
A subclone of HIV-1-infected U937 cells, U1, was donated by
Thomas Folks and was obtained from the AIDS Research and Ref-
erence Program, MAID, National Institutes of Health, Bethesda,
MD. This cell line shows a minimal amount ofconstitutive expres-
sion of HIV-1 (9).
A variant of the CEM T-cell line, A3.01, was infected with the
LAV strain of HIV-1 and a subdone, ACH-2, was obtained that
exhibits minimal amounts ofconstitutive expression ofHIV-1 (10) .
This cell line was donated by Thomas Folks and was obtained from
the AIDS Research and Reference Program, NIAID, NIH.
Plasmids. The plasmid HIV-CAT, containing the HIV=1-LTR
upstream ofthe chloramphenicol acetyl transferase (CAT) gene has
been described (4). The plasmid, HIVNF-KBA CAT, with muta-
tions in the NF-KB sites, rendering these sites unable to bind the
NH-KB protein, has also previously been described (4).
A plasmid 018) containing two KB sites from the K enhancer
which were cloned into Hind III and Sal I sites upstream ofa trun-
cated mouse c-fos promoter linked to the CAT gene, was kindly
provided by J. Pierce (21) . The cfos promoter was truncated to
nucleotide 56 toremove phorbol ester and serum-responsive ele-
ments. A plasmid lacking KB sites but retaining the truncated cfos
promoter was also obtained from J. Pierce, Whitehead Institute,
Cambridge, MA (21) .
Transfections and CATAssays. All cell lines were transfected using
DEAE-dextran . In brief, cells were washed twice with PBS and
resuspended in serum-free suspension Tris-buffered saline (22) . 10'
cells were then treated with DEAE-Dextran at 200 ug/ml (Phar-
macia, Uppsala, Sweden) containing 10 Wg of plasmid in 1 ml .
Cells were treated 90 min at 37 °Cwith frequent mixing. A 10%
DMSO shock was performed and the cells were washed twice with
PBS and then resuspended to a concentration of 5 x 10 5 cells/ml
in RPMI 1640 media with 10% FCS.
24 h after transfection, the cells were exposed to either LPSEsch-
erichia coli 0127:B8 (Difco Laboratories, Detroit, MI), recombinant
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human TNF-a(Genzyme Corp., Cambridge, MA), or PMA(Sigma
Chemical Co., St . Louis, MO) and PHA (Sigma). Some transfec-
tions received no treatments. A rabbit anti-human TNF-a neu-
tralizing antibody (1 pl neutralizes 10' U of TNF-a) was also
added to some transfections (Genzyme Corp .) . 44 h after transfec-
tion, cell extracts were prepared for CAT assay and protein concen-
trations were determined by the method of Bradford (23) (Bio-
Rad Laboratories, Richmond, CA). The quantity of protein used
per assay was normalized (70 jug for U937 and THR1 cells and
100 ttg for Jurkat cells) . CAT assays were performed according to
the method of Gorman et al . (24) . Percent conversion of acetylated
products by liquid scintillation was calculated .
Transfections were performed between two and six times and
results are reported as the arithmetic mean + SEM.
Cellular Extracts and Electrophoretic Mobility Shift Assays(EMSA).
Cellular extracts were prepared from 5 x 10' cells with or without
treatment for various time periods with GM-CSF (Genetics Insti-
tute, Cambridge, MA), LPS, or PMA plus PHA according to a
protocol, with some modifications, described by Baeuerle and Bal-
timore (25) . Cells were washed twice with ice-cold PBS and then
resuspended in lysis buffer that consisted of 20 mM Hepes (pH
7.9), 0.35 M NaCl, 20% glycerol, 1% NP-40, 1 MM MgC12,
1 mM DTT, 0.5 mMEDTA,0.1 mM EGTA,1 mM PMSF, 0.3 jug/
ml antipain (Sigma), and0.3 I~g/ml leupeptin (Sigma). After lysis
on ice for 10 min, particulate material was removed by centrifuga-
tion at 11,000g for 15 min at 4°C. The supernatant's protein con-
tent was measured by an assay using bicinchoninic acid according
to the manufacturer's instructions (Pierce Chemical Co., Rockford,
IL). Electrophoretic mobility shift analyses to detect NF-rcB binding
were carried out as previously described (26) .
The 32 P-labeled DNA probe was a 44-bp HindIII-Sall fragment
cut from a plasmid 010), containing a single «B enhancer site up-
stream of the mouse cfos promoter (21) . This fragment was end-
labeled with (32P]CTP and [32P]ATP (New England Nuclear,
Boston, MA) using the Klenow fragment of E. coli DNA poly-
merase I (Boehringer-Mannheim Biochemicals, Indianapolis, IN).
Bands other than free probe and NK-KB activity are noted with
cellular extracts made with this method . They represent cytoplasmic
DNA binding proteins and/or proteolytic digestion products of
nuclear proteins (Feinberg, M., and D. Baltimore, manuscript in
preparation) .
The competition experiments were performed with various nano-
gram amounts of an unlabeled double-stranded oligonucleotide con-
taining both HIV-1 NP-0-binding motifs and an oligonucleotide
with mutations in the HIV-1 NF-KB-binding motifs, previously
shown to not bind NF-KB (4) (kindly providedby Dr.M. Lenardo) .
HIV-1 KB oligonucleotide : 5'TCGACAAGGGACTTT000CTG-
GGGACTTTCCAGGGC3'. Mutant HIV-1 KB oligortudeotide :
5'TCGACAACTCACTTTCCGCTGCTCACTTTCCAGGC3'.
Stimulation ofHIVI Expressionfrom U1 andACH-2 Cell Lines. 5
x 105 were seeded in 2 ml of medium in 24-well plates (Costar,
Cambridge, MA). They were either left untreated or a variety of
agents were added including TNF-ac, LPS, and PMA plus PHA.
After 24 h, samples of supernatants were removed daily for 3 d.
The p24 antigen level was measured using a sensitive ELISA method
(Dupont, Wilmington, DE) following the manufacturer's instruc-
tions. Some cultures were pretreated with GM-CSF for 24 h be-
fore other agents were added. AntiTNF-a neutralizing antibody
(Genzyme Corp.) was added where indicated .
Each experiment was repeated at least twice using duplicate or
triplicate samples per experiment . Datapresented represent the arith-
metic mean ± SEM.
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Results
Activation ofHIV1-LTR by LPS in Monocyte/Macrophage-
like Cell Lines. To examine the effect of LPS on HIV1-
LTR-directed gene expression, various cell lines were trans-
fected with an HIV1-LTR CAT construct . LPS (10 hg/ml)
greatly increased the amount ofCAT activity produced from
this HIV1-LTR CAT construct after transient transfection
of both U937, and the phenotypically more mature THP-1
cell lines (Fig . 1, A and B) . PMA plus PHA (50 ng/ml and
2 wg/ml) and TNF-a (1,000 U/ml) also stimulated CAT
production in both cell lines, but to lesser degrees than LPS
(Fig. 1, A and B) . Our ability to demonstrate HIV1-LTR
CAT stimulation by PMA and PHA in THP-1 cells is at vari-
ance with a previous report (7) . A concentration of TNF-ci
of 1,000 U/ml, as illustrated in Fig. 1, resulted in the greatest
level of stimulation in a dose-response curve with this cytokine.
Above this level cytotoxicity was evident (data not shown) .
Mock transfections consistently gave percent conversion levels
of <1%.
To determine whether LPS could induce CAT activity in
T cells, Jurkat cells were transfected with the HIV1-LTR
CAT plasmid . CAT activity was not stimulated by LPS (10
wg/ml) in Jurkat cells, although PMA and PHA, as previ-
ously demonstrated (4), stimulated CAT activity in this cell
255
line (Fig . 1 C) . TNF-ot was also demonstrated to stimulate
the HIV1-LTR-directed CAT gene in Jurkat cells (data not
shown) .
To determine whether LPS might stimulate HIV1-LTR
CAT at physiologically significant concentrations, various
amounts of LPS were added to transient transfections . LPS
was able to stimulate HIV1-LTR CAT in U937 cells to a
significant degree at concentrations as low as 10 pg/ml. This
effect was not evident at 1 pg/ml (Fig. 2) . Stimulation de-
creased over the range of LPS concentrations from 100 ng
to 10 pg/ml.
To examine whether the KB sites in the HIV1-LTR were
necessary for LPS-induced CAT stimulation, an HIV1-LTR
CAT construct with mutant NF-KB binding sites (4) (HIV-
NF-KB A CAT) was transfected into U937 and THP-1 cells .
LPS (10 hg/ml), when added 24 h after transfection, led to
no significant stimulation in CAT activity in U937 or THR1
cells (Fig . 1, A and B) . CAT activity from this construct
was also not stimulated above baseline by TNF-ca or PMA
and PHA treatment in the U937 and THP-1 cell lines (data
not shown) .
To examine whether regions other than the KB sites in the
HIV1-LTR were required for LPS-induced CAT stimulation,
a plasmid U18) containing two KB sites from the is enhancer
Figure 1 .
	
CAT stimulation in transient transfections of U937, THP-1, and Jurkat cells. (A) U937
cells, (B) THP-1 cells, (C) Jurkat cells . 107 cells were transfected with 10 ug of various plasmids andtreated with different agents at 24 h (PMA 50 ng/ml and PHA 2 kg/ml, TNF-a 1,000 U/ml, or LPS
10 P.g/ml) . Cell extracts were harvested for CAT assays 44 h after transfection (see Materials and
Methods) . The level of endotoxin in the medium and the FCS was 0 .3 and 1 .4 endotoxin units (EU)
per milliliter, respectively. The level of endotoxin in the TNF-a was <0.001 EU per unit of TNF-a .
The percent conversion of [ 14C]chloramphenicol was measured and bar graphs illustrate the arithmetic
mean of between two and six separate experiments + SEM . The transfections not treated with any
agent are noted at the bottom of the graph by a negative sign . The "fold increase shown at the
bottom of HIVCAT transfections represent the increased conversion of [t4C]chloramphenicol comparedwith the untreated HIV-CAT transfections which are given the value of 1 . HIV-CAT plasmid is a HIV1-
LTR linked to a CAT gene. The HIV NF-KB A CAT plasmid is an HIV1-LTR with mutations in both
KB sites linked to a CAT gene . Fos NF-KB CAT plasmid (J18) contains two KB sites upstream of a trun-
cated c fos promoter linked to the CAT gene.
Pomerantz et al .
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Figure 2 .
	
Dose response of HIVCAT stimulation by LPS in U937
cells. 107 U937 cells were transfected with 10 jig of the HIV-CAT
plasmid . 24 h after transfection, various amounts of LPS were added
to give differing final concentrations of LPS in the medium. Cell ly-
sates were harvested 44 h after transfection . Percent conversions of
[t4C]chloramphenicol are the arithmetic means + SEM of three inde-
pendent transfections .
upstream ofa truncated cfos promoter linked to a CAT gene
(21) was transfected into U937 and THR1 cells . When treated
with LPS (10 Wg/ml), a large stimulation of CAT activity
in U937 and THP-1 cells was demonstrated (Fig. 1, A and
Figure 3 . AntiTNF-a antibody treatments of HIV-CAT transfec-
tions in U937 cells. U937 cells were transfected with 10 jig of HIV
CAT plasmid and treated with LPS or TNFa, with or without anti-
TNFa antibody, 24 h after transfection . 20 Fl of antiTNF-a anti-
body, which neutralizes 2 x 10 4 U of TNF-a, were added to appro-
priate transfections . (Lane 1) No treatment, (lane 2) LPS (10 kg/ml),
(lane 3) LPS + antiTNF-a antibody, (lane 4) TNF-a (1,000 U/ml),
and (lane 5) TNF-ot + antiTNF-a antibody. The percent conver-
sions of [t4 C]chloramphenicol are the arithmetic means t SEM of
three independent transfections . The autoradiograph shown is a repre-
sentative example of these experiments.
256 Lipopolysaccharide and Human Immunodeficiency Virus
B) . A plasmid lacking the KB sites but retaining the cfos pro-
moter linked to a CAT gene (21) was not stimulated by LPS
in either cell line (data not shown) .
Transfections of the HIV-NF-KB A CAT andJ18 plasmids
indicate that the LPS stimulation of the HIV1-LTR CAT
in the U937 and THP-1 cell lines is based on the induction
ofNF-KB and its binding to KB enhancer motifs in the LTR .
To ascertain ifthe LPS-induced CAT stimulation was caused
by TNF-ci released from cells, HIV1-LTR CAT constructs
were transfected into U937 cells, which were then either treated
with LPS (10 pg/ml) plus or minus anti-TNF-ot antibody,
TNF-ci (1,000 U/ml) plus or minus antiTNF-a antibody,
or left untreated (Fig . 3) . AntiTNF-a antibody had no
significant effect on LPS-induced stimulation of HIV1-LTR
CAT but reduced by r-86% the level of CAT activity in-
duced by TNF-ot (Fig. 3) . AntiTNF-ci antibody was also
unable to block LPS-induced CAT stimulation in the THP-1
cell line (data not shown) .
LPS Induces an Activity in Monocyte/Macrophage-like Cell
Lines that Binds to KB sites on EMSA. Cellular extracts were
prepared by a brief protocol (25), rather than the nuclear
extracts prepared by the method of Dignam et al . (27), for
EMSA. This method gave more background bands but al-
lowed the use of small amounts of cells and minimized
proteolysis common in the manipulation of monocyte/
macrophage-like cell lines . A binding activity, indistinguish-
able from NF-KB, was found in extracts ofU937 and THP-1
cells treated with LPS but not Jurkat cells.
This binding activity was induced after only 30 min of
LPS treatment of U937 cells and increased over treatment
periods up to 2 h (Fig. 4, lanes 2-4) . Prolonged treatment
with LPS showed persistent but reduced levels of NF-KB-like
binding activity (Fig . 4, lane 5) .
NF-KB-like binding activity was also detected in THP-1
cells stimulated with LPS (Fig . 4, lane 12), but contrary to
a previous report (7), little of this activity was found in our
unstimulated THP-1 cells (Fig. 4, lane 11) . This LPS-inducible
complex comigrated with a PMA plus PHA-inducible com-
plex in U937, THP-1, andJurkat cells (Fig. 4, lanes 10, 17,
19) . Peak levels of NF-KB-like activity were induced by
PMA/PHA in U937 and THP-1 cells with overnight treat-
ment, while PMA/PHA treatment gave its greatest effect
in Jurkat cells after 2 h (data not shown) . LPS is a much
more potent stimulus for NF-«B-like binding activity in U937
and THP-1 cells than PMA plus PHA. LPS was unable to
stimulate NF-KB-like binding activity inJurkat cells (Fig. 4,
lane 20) .
The LPS-inducible complex was specifically competed away
by . an unlabeled fragment composed of both KB sites from
the HIV1-LTR in reactions with cellular extracts from both
U937 and THP-1 cells (Fig. 4, lanes 6-8 and 13-15) . An un-
labeled fragment with mutations in the KB sites of the HIV1-
LTR was unable to compete with this binding activity from
LPS-stimulated U937 and THP-1 cells (Fig . 4, lanes 9 and
16) . The unlabeled competitor fragment effectively competed
with binding activity found in PMA plus PHAtreatedJurkat
cell extracts, while the mutant unlabeled fragment showed
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Figure 4 .
	
Electrophoretic mobil-
ity shift assays of U937, THP-1,
and Jurkat cells . 5 x 107 cells in
50 ml of medium were treated
with various agents over differing
time periods. Cellular extracts
were prepared and EMSAs per-
formed as described in Materials
and Methods .
(Lane 1) U937, no treatment
(noted by negative [-] sign).
(Lanes 2-5) U937 + LPS (10 t~g/
ml) over various stimulation time
periods. (Lanes 6-8) U937 + LPS
and differing amounts of unlabeled
competitor (comp.) . (Lane 9) U937
+ LPS and 20 ng of mutant unla-
beled competitor. (Lane 10) U937
+ PMA (50 ng/ml) plus PHA (2
Fag/ml) overnight stimulation .
(Lane 11) THP-1, no treatment .
(Lane 12) THP1 + LPS, 2 h stim-
ulation. (Lane 13-15) THP-1 +
LPS and differing amounts of un-
labeled competitor. (Lane 16)
THP-1 + LPS and 20 ng of mu-
tant unlabeled competitor. (Lane
17) THP-1 + PMA and PHA
overnight stimulation . (Lane 18)
Jurkat, no treatment . (Lane 19)
Jurkat + PMA and PHA, 2 h
stimulation . (Lane 20) Jurkat +
LPS, 2 h stimulation . (Lane 21)
Jurkat + PMA and PHA 20 ng competitor. (Lane 22) Jurkat + PMA and PHA and 20 ng mutant competitor. The autoradiograph illustrated
was slightly overexposed to demonstrate changes in the NF-KB band in lanes where various amounts of unlabeled competitor were added . (Filled
arrowheads) NF-KB band; (open arrowheads) unbound probe.
no competition with this binding activity (Fig. 4, lanes 21
and 22) . The above data demonstrate that LPS induces a
binding activity indistinguishable from NF-KB in mono-
cyte/macrophage-like cell lines .
Stimulation ofHIVI Production by LPS in UI Cells Pretreated
with GM-CSF. The U1 cell line is a subclone of HIV-1-in-
fected U937 cells which constitutively produce very low
amounts of virus . These cells can be stimulated to produce
much greater amounts of HIV-1 by treatment with TNF-a,
PMA, and GM-CSF (7, 9) .
We were able to reproduce these findings. We noted a 320-
and 27-fold increase in p24 antigen levels over baseline with
TNF-a and GM-CSF, respectively (Fig . 5, A and B) . PMA
plus PHA induced p24 antigen levels to >100 ng/ml by day
3 (data not shown) . LPS alone, however, failed to yield a con-
sistent increase in p24 antigen levels (Fig . 5 A). There was
<0.2 ng/ml of p24 antigen in the supernatant of unstimu-
lated U1 cells by the third day in culture.
Reasoning that the U1 cell line might be a relatively im-
mature subclone of U937 cells, we attempted to differentiate
this cell line using GM-CSF before treatment with LPS. After
treatment for 24 h with GM-CSF, LPS led to a 200-fold in-
crease in p24 antigen levels in the supernatant compared with
untreated cultures, and a 7.4-fold increase compared with cul-
tures treated solely with GM-CSF by day 3 after LPS treat-
257 Pomerantz et al .
ment (Fig . 5 B) . We were further able to demonstrate that
after GM-CSF pretreatment, HIV-1 production could be fur-
ther augmented in the U1 cell line with concentrations of
LPS as low as 100 pg/ml (Fig. 6) . All ofthe stimulatory effects
on HIV-1 production in the U1 cell line resulted in increased
levels of HIV-1-specific RNA (Pomerantz, R.J ., D . Trono,
M. Feinberg, and D. Baltimore, manuscript submitted for
publication) .
To examine whether the LPS-mediated stimulation ofHIV-1
in U1 cells was due to the release of TNF-a from the GM-
CSF-treated UI cells, we added antiTNF-a neutralizing an-
tibody to cultures treated with GM-CSF plus LPS . This an-
tibody had a minimal effect on the level of virus production
in GM-CSF pretreated cells to which LPS was added, although
it was able to totally ablate the stimulation of virus produc-
tion induced by 1,000 U/ml of TNF-a (Fig. 5, A and B) .
A chronically HIV-1-infected T cell line, ACH-2, which
constitutively produces small amounts ofvirus, was also treated
with a variety of agents. Although TNF-a led to a significant
increase in viral production, LPS alone, GM-CSF alone, and
GM-CSF plus LPS had no effect on viral replication (Fig. 5 C) .
Stimulation ofNF-KB-like Binding Activity in UI Cells by LPS
afterPretreatment with CM. CSF. To demonstrate that the LPS-
mediated increase in HIV-1 production in U1 cells pretreated
with GM-CSF was correlated with the activation of NF-KB,
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Figure 5 . Production of HIV-1 from the U1 and ACH-2 cell lines.
(A and B) Ll1 cells, (C) ACH-2 cells. 5 x 105 cells were placed in
2 ml of medium in 24-well plates. Different agents were added and
p24 antigen levels in the supernatants were determined daily for 3 d .
The treatment regimens included LPS (10 ug/ml) with or without
258 Lipopolysaccharide and Human Immunodeficiency Virus
cellular extracts were made after a variety of treatment pro-
tocols and the binding reactions to a labeled probe with 2
KB sites were studied by EMSA.
LPS alone was unable to induce NF-«B-like activity in U1
cells (Fig. 7, lane 2) . NF-KB-like activity was not stimulated
by LPS alone in U1 cells after 1, 2, 6, 24, and 36 h of treat-
ment (data not shown) . As previously reported (7), a small
amount of NF-KB-like activity was induced in the U1 cell
line after 24 h of treatment with PMA and PHA (Fig. 7,
lane 4) .
As reported for other cell lines (6), treatment of the U1
cell line for 48 h with GM-CSF did not induce NF-KB-like
activity (Fig. 7, lane 3) . GM-CSF did not induce NF-KB-like
activity in U1 cells when treated for time periods ofbetween
2 and 36 h (data not shown) . LPS, though, was able to in-
duce a small quantity ofNF-KB-like activity after the U1 cells
were pretreated for 24 h with GM-CSF (Fig. 7, lane 5) . LPS
induced NF-KB-like activity in GM-CSF pretreated U1 cells
only if added to the medium for 24 h or longer (data not
shown) .
This NF-«B-like activity comigrated with a band induced
by PMA plus PHA in Jurkat cells (Fig. 7, lane 9) and was
specifically competed away with an unlabeled DNA fragment
with two KB sites from the HIV1-LTR but not a fragment
with mutations in these KB sites (Fig. 7, lanes 6 and 7) . This
DNA binding activity was, therefore, indistinguishable from
NF-KB. In multiple experiments, only relatively small quan-
tities of NF-KB were induced by PMA plus PHA or GM-
CSF plus LPS in the U1 cell line compared with levels in-
duced in uncloned and uninfected U937 cells.
To further demonstrate that NF-KB was activated by PMA
plus PHA and GM-CSF plus LPS in U1 cells, these cells were
transfected with the Fos NF-KB CAT (J18) plasmid . Treat-
ment of these treatment transfections with PMA plus PHA
or GM-CSF plus LPS led to a significant stimulation of CAT
activity. Treatment with GM-CSF alone or LPS alone did
not stimulate CAT activity (data not shown) .
Discussion
We have demonstrated here that LPS potently activates the
HIV1-LTR in monocyte/macrophage-like cell lines but not
in a T cell line. The LPS effect appears to be mediated through
NF-KB. LPS increased HIV-1 production from a cloned mono-
cyte/macrophage-like cell line which was pretreated with GM-
CSF. These LPS effects were demonstrated at picogram per
milliliter concentrations .
LPS, which is a major constituent ofthe cell walls of gram
negative bacteria, has a plethora ofeffects on a variety ofcells .
The release of TNF-ca from monocyte/macrophages by LPS
antiTNF-a antibody (4 Al), TNF-a (1,000 U/ml) with or without
antiTNF-a antibody, GM-CSF (500 U/ml) alone, and GM-CSF
(500 U/ml) for 24 h followed by LPS (10 ug/ml) . Certain cultures
were left untreated . The level of endotoxin in the GM-CSF was
<0.001 EU per unit of GM-CSR Data points represent the arithmetic
means ± SEM of two to three separate experiments performed in
duplicate.
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Figure 6 .
	
Dose response of HIV-1 production in GM-CSF
pretreated U1 cells by LPS. Various amounts of LPS were added to
U1 cells pretreated with GM-CSF (500 U/ml) for 24 h . p24 antigen
levels were measured from these supernatants on the third day after
LPS was added . Each bar is the arithmetic mean + SEM of two ex-
periments performed in duplicate .
leads to many but not all the pathophysiologic effects noted
during endotoxemia (28, 29) . LPS activates macrophages and
induces Interleukin I, Interleukin 6 and Interferon ti produc-
tion (29, 30) . LPS is also a murine B lymphocyte mitogen
and will activate protein kinase C and induce NF-KB in pre-
B cells although it has little effect on T lymphocytes (31) .
Many of these LPS-induced effects are seen with nanograrn
or picogram per milliliter concentrations (28, 29) . LPS may
not activate NF-KB in T cells for lack of an LPS receptor
or for other reasons.
Since LPS induces production ofTNF-a (28) and TNF-a
was able to activate transcription of our HIV-1-CAT con-
struct, it could be that the effect ofLPS on HIV1-LTR-driven
transcription is indirect . An antibody to TNF-a did not block
the LPS-induced HIV1-LTR CAT stimulation . Moreover,
EMSAs demonstrated that LPS activation of NF-KB begins
within 30 min or less of treatment . It is not likely, therefore,
that an LPS-induced increase in production or release ofTNF-a
is the major mechanism underlying this effect . The TNF-a
promoter itself has KB-like regions (32), and consequently,
both stimulation of TNF-a and stimulation of HIV-1 may
be independent results of LPS-mediated NF-KB activation .
A recent report has demonstrated that LPS-treated primary
macrophages produce cytokines, including TNF-a, which
stimulate HIV-1 production in T lymphocytes (10) . This is
certainly a possible mechanism by which LPS stimulation of
some monocyte/macrophage populations might affect not only
HIV-1 production directly in monoryte/macrophages but also
have an indirect effect on HIV-1 replication in T lympho-
cytes in vivo .
It is instructive to note that a significant effect on HIV-1
production was not demonstrated when the U1 cell line was
treated with LPS alone . Only after pretreatment with GM-
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Figure 7 . EMSA of U1 cells . (Lane 1) U1 cells, no treatment .
(Lane 2) U1 cells treated with LPS (10 ug/ml) for 48 h . (Lane 3) U1
cells treated with GM-CSF (500 U/ml) for 48 h . (Lane 4) U1 cells
treated with PMA (50 ng/ml) and PHA (2 Ftg/ml) for 24 h . (Lane
5) U1 cells treated with GM-CSF for 24 h then LPS for 24 h . (Lanes
6 and 7) U1 cells pretreated with GM-CSF for 24 h and then LPS
for 24 h plus 20 ng of unlabeled competitor (comp) or mutant com-
petitor (mut. comp), respectively. (Lane 8) Jurkat, no treatment . (Lane
9) Jurkat plus PMA and PHA for 2 h . This representative autoradio-
graph was slightly overexposed to properly illustrate the small quan-
tity of NF-KB that was activated in U1 cells (uppermost band in
lanes 4, 5, and 7) . (Closed arrowheads) NF-KB band; (open arrowheads)
unbound probe.
CSF, which has been noted to induce differentiation and matu-
ration in monocytic precursor cells (33), was LPS able to stimu-
late high levels of HIV-1 production. It appears that the U1
cell subclone of HIV-1-infected U937 cells may be quite im-
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mature and either lack an LPS receptor or some component
of the proximal NF-KB activation pathway induced by LPS.
Only after maturation by GM-CSF can the U1 cell line re-
spond to LPS with an increase in HIV-1 production from
its integrated provirus. As with the HIV1-LTR CAT trans-
fections, the LPS-effect on viral production is largely a direct
one and is not mediated via a release of TNF-a. An anti-
TNF-a antibody was able to decrease only slightly the level
ofHIV-1 production in the U1 cell line pretreated with GM-
CSF to which LPS was added . Only if endogenously pro-
duced TNFci is more difficult to neutralize compared with
exogenous TNF-a might a portion of the LPS effect still be
mediated through TNF-oc .
A recent study has demonstrated that pretreating primary
macrophages with LPS may protect them from HIV-1 infec-
tion, possibly through activation (13) . This study is not at
variance with our data . Treatment of macrophages with LPS
before infection with HIV-1 may have a different effect on
HIV-1 production than treatment ofchronically HIV-1-infected
monoryte/macrophages. That LPS may protect macrophages
from HIV-1 infection and increase HIV-1 production from
chronically infected monoryte/macrophages suggests that, in
vivo, the effects of LPS on HIV-1 may be complex .
The induction of NF-KB as the cellular mediator of the
LPS effect on HIV-1 production in monoryte/macrophage-
like cells is yet another system controlled by this transcrip-
tional regulator (for review see reference 34) . The induction
of NF-KB does not require protein synthesis, and probably
occurs through the release of an inhibitor (IKB), bound to
NF-KB (25) . The free form of NF-KB may then migrate to
the nucleus where it binds to 10 or 11 by enhancer-motifs
present in a variety ofpromoters. These include HIV-1, CMV,
IFN-/3, IL2, and the human IgK enhancer, to name but a
few (34) .
NF-KB activation takes place via more than one pathway
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